Pfizer Inc.

09/27/2021 | Press release | Distributed by Public on 09/27/2021 04:46

Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults